Biosurfactants as a Novel Additive in Pharmaceutical Formulations: Current Trends and Future Implications

Author(s): Shubham Thakur, Amrinder Singh, Ritika Sharma, Rohan Aurora, Subheet Kumar Jain*

Journal Name: Current Drug Metabolism

Volume 21 , Issue 11 , 2020

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: Surfactants are an important category of additives that are used widely in most of the formulations as solubilizers, stabilizers, and emulsifiers. Current drug delivery systems comprise of numerous synthetic surfactants (such as Cremophor EL, polysorbate 80, Transcutol-P), which are associated with several side effects though used in many formulations. Therefore, to attenuate the problems associated with conventional surfactants, a new generation of surface-active agents is obtained from the metabolites of fungi, yeast, and bacteria, which are termed as biosurfactants.

Objectives: In this article, we critically analyze the different types of biosurfactants, their origin along with their chemical and physical properties, advantages, drawbacks, regulatory status, and detailed pharmaceutical applications.

Methods: 243 papers were reviewed and included in this review.

Results: Briefly, Biosurfactants are classified as glycolipids, rhamnolipids, sophorolipids, trehalolipids, surfactin, lipopeptides & lipoproteins, lichenysin, fatty acids, phospholipids, and polymeric biosurfactants. These are amphiphilic biomolecules with lipophilic and hydrophilic ends and are used as drug delivery vehicles (foaming, solubilizer, detergent, and emulsifier) in the pharmaceutical industry. Despite additives, they have some biological activity as well (anti-cancer, anti-viral, anti-microbial, P-gp inhibition, etc.). These biomolecules possess better safety profiles and are biocompatible, biodegradable, and specific at different temperatures.

Conclusion: Biosurfactants exhibit good biomedicine and additive properties that can be used in developing novel drug delivery systems. However, more research should be driven due to the lack of comprehensive toxicity testing and high production cost which limits their use.

Keywords: Biosurfactants, regulatory status, lipopeptides, glycolipids, cremophor EL, transcutol-P.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Published on: 29 December, 2020
Page: [885 - 901]
Pages: 17
DOI: 10.2174/1389200221666201008143238
Price: $65

Article Metrics

PDF: 37